KRAS and biliary tract cancer: In a phase I/II basket trial (NCT03785249) of KRAS G12C inhibitor adagrasib, 42 patients with KRAS G12C positive gastrointestinal cancers including eight biliary tract cancer cases were enrolled in a phase II cohort.